Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.
This guidance replaced NICE technology appraisal guidance on tocilizumab for the treatment of rheumatoid arthritis (TA198).
This guidance has been updated by NICE technology appraisal guidance on adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375).
We reviewed the evidence in September 2013 and found nothing new that affects the recommendations in this guidance.
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.